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Abstract
Over-expression of DNA repair genes has been associated with resistance to radiation and DNA-damage induced by
chemotherapeutic agents such as cisplatin. More recently, based on the analysis of genome expression profiling, it was
proposed that over-expression of DNA repair genes enhances the invasive behaviour of tumour cells. In this study we
present experimental evidence utilizing functional assays to test this hypothesis. We assessed the effect of the DNA repair
proteins known as X-ray complementing protein 3 (XRCC3) and RAD51, to the invasive behavior of the MCF-7 luminal
epithelial-like and BT20 basal-like triple negative human breast cancer cell lines. We report that stable or transient over-
expression of XRCC3 but not RAD51 increased invasiveness in both cell lines in vitro. Moreover, XRCC3 over-expressing MCF-
7 cells also showed a higher tumorigenesis in vivo and this phenotype was associated with increased activity of the
metalloproteinase MMP-9 and the expression of known modulators of cell-cell adhesion and metastasis such as CD44, ID-1,
DDR1 and TFF1. Our results suggest that in addition to its’ role in facilitating repair of DNA damage, XRCC3 affects
invasiveness of breast cancer cell lines and the expression of genes associated with cell adhesion and invasion.
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Introduction
Breast cancer is the leading cause of tumour-related death
among women worldwide [1]. In Canada, breast cancer is the
second cause for mortality after lung cancer and is the most
frequently diagnosed cancer in women with a 2% increase of new
diagnosed cases in respect to the 2009 statistics [2].
Currently therapeutic approaches are limited by the develop-
ment of drug resistance and progression of the majority of tumours
to a more invasive and aggressive phenotype [3]. Resistance to
anticancer agents that induce DNA damage has been associated
with increased expression of DNA repair genes [4,5,6,7] and the
development of aggressive/metastatic behaviour in at least four
different types of tumours [8,9,10,11,12,13,14]. Recently, using
gene expression profiling of human primary malignant melanoma,
Sarasin and Kauffman [12] hypothesised that aberrant expression
of genes connected with DNA repair pathways is associated with
increased metastatic potential. In particular, over-expression of
genes involved in double-strand break (DSB) repair and
surveillance of DNA replication forks were associated with an
increased tendency to generate highly malignant metastatic cancer
cells and poor patient survival prognosis [9,11,14]. Although this
concept has been hypothesized repeatedly there remains little
experimental evidence to support it [12,15].
The two major DNA repair pathways involved in the repair of
DSB are the DNA homologous recombinational repair pathway
(HRR) and the nonhomologous DNA end-joining (NHEJ)
pathway. A functional link between a NHEJ DNA repair
component and phenotypic changes in human cancer cells have
been made. It has been shown that a component of the NHEJ
repair complex, the protein KU80, is involved in cell-cell and cell-
matrix adhesion [16,17]. In addition to its central role in DNA
DSB repair, KU80 co-localizes with metalloproteinase 9 (MMP-9)
on the outer cell membrane and plays an important role in
regulating extracellular matrix remodelling in highly invasive
hematopoietic cells [16,18]. MMP-9 mediates invasion of
mammary carcinoma cells and invasion/angiogenesis of kerato-
cyte tumours by binding to the hyaluronan receptor, CD44
[19,20]. The reported association of the KU80/MMP-9 complex
with the invasiveness of cancer cells is the first evidence linking
DNA repair proteins with cellular invasiveness.
XRCC3 is a RAD51 paralog that participates in the HRR
pathway [5,21,22,23]. RAD51 catalyzes the invasion of an
undamaged DNA template during homologous recombination, a
crucial step leading to repair of a broken DNA. RAD51
localization to DSBs depends on the function and its direct
interaction with XRCC3 [24]. XRCC3 has been reported to
interact as well with BRCA2, FANCD2 and FANCG to form a
discrete complex related to HRR and chromosome stability
[24,25]. It is known that XRCC3 expression levels are associated
with increased DNA repair and resistance to the DNA damaging
agents such as cisplatin and melphalan [7,26,27].
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unknown, we explored the phenotypic effect resulting in the over-
expression of XRCC3 and RAD51 on different breast cancer cell
lines, vis- ˆ-vis invasiveness. Specifically, we over-expressed XRCC3
in two breast cancer cell lines, MCF-7 and BT20, with contrasting
phenotypes and clinical prognosis [28]. MCF-7 is a luminal
epithelial-like cell line which is positive for HER2, oestrogen and
progesterone receptors expression while BT20 is a triple negative
basal-like cell line, negative for HER2, oestrogen and progesterone
receptor expression. Though both cell lines have contrasting
phenotypes and clinical prognosis [28] they showed an increase in
their invasiveness behaviour that was dependent of XRCC3 over-
expression. The following study is the first report that test the
hypothesis that over-expression of DNA repair genes enhances the
invasive behaviour of tumour cells [9,11,12,15].
Materials and Methods
Breast cancer cell lines
The breast cancer cell lines, MCF-7 and BT20 were purchased
from American Type Culture Collection (ATCC) and cultivated in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS) (Gibco) in a humidified incubator maintained at 37uC and
5% CO2. Stably transfected pCDNA3.0-XRCC3 over-expressing
and pCDNA3.0 MOCK MCF-7 cell lines produced in a previous
study were used to investigate the effects of XRCC3 over-
expression on the tumorigenesis and metastasis of breast cancer
cells [7]. We also used transiently transfected XRCC3 and RAD51
MCF-7 and BT20 cells, the parental cell lines were obtained from
American Type Culture Collection (ATCC). In this case, MCF-7
and BT20 cells were transfected with pCDNA3.0 or pCDNA3.0
carrying the XRCC3 cDNA or RAD51 cDNA using Superfect or
Lipofectamine 2000 according to the manufacturer’s directions.
Briefly, cells were plated at a density of 2610
6 cells/plate on
100 mm tissue culture dishes. After overnight incubation, the
transfection mix containing 30 mg of plasmid DNA was applied.
Cells were incubated for an additional 48 hrs and harvested.
Over-expression of XRCC3 and RAD51 protein in stably or
transiently transfected MCF-7 and BT20 cells was confirmed by
Western blot analysis.
Western Blotting
Basal expression level of proteins related with DNA repair and
cell-matrix adhesion were characterised by Western blots. Aliquots
(100 mg protein) of cell lysate were loaded onto 4-12% gradient
acrylamide gels. After each electrophoresis and transfer, the
following antibodies were used: from Cell Signalling, MMP-9 that
recognizes the pro enzyme (92 kDa) and the cleaved active form
(84 kDa); from Santa Cruz Biotechnology, Inc, anti-ID-1 (C-20),
DDR1 (C-20), RAD51 (sc8349) and anti-Actin (I-19); from
Oncogen, we used anti-XRCC3 (Oncogen, San Diego, CA. Ab-
1); from Neomarkers KU70 (Ab4- MS 329- P0) and KU80 (Ab7-
MS 332-P0). Goat anti-Actin (Santa Cruz Biotechnology, Inc) or
mouse monoclonal antibody against GAPDH (Research Diagnos-
tics) was used to confirm protein loading and the blots were
visualized using peroxidase substrate system (ECL Western
blotting detection reagents, Millipore).
Matrigel invasion assays
Matrigel-coated invasion chamber plates of 8.0-mm pore size
(BD Bioscientific) were used for the invasion assay. Cells (5610
4
cells/0.5 mL) were plated in the top chamber in FBS-free RPMI
1640 media and culture medium with 10% FBS RPMI 1640 was
used in the bottom chamber as a chemo-attractant. Forty-eight
hours later, cells were fixed using a 3.7% formaldehyde solution
and stained using Hematoxylin-EosinY (Thermo Scientific). Cell
numbers were counted over four fields of the porous membrane
and photographed. As in previous reports, MDA MB-436 cell line
was used as a positive control [29]. The invasion assay was
replicated on stably transfected MOCK and XRCC3 OE MCF-7
and on MOCK, XRCC3 and RAD51 OE transiently transfected
MCF-7 and BT20 cells.
Gene silencing of XRCC3 gene by small interference RNA
RNAi-mediated knockdown of XRCC3 was conducted using a
siRNA (Dharmacon) with CAGAATTATTGCTGCAATTAA as
a target sequence. As negative control, a non-silencing siRNA
(Dharmacon) with target sequence CGTCATATACCAAGC-
TAGTT was used. Transfection was performed using Oligofecta-
mine (Invitrogen), according to the manufacturer’s protocol with
minor modifications. We selected the MCF-7 over-expressing cell
as it was previously reported that the silencing of Xrcc3 gene
showed to reduce the proliferation of MCF-7 cells by the
accumulation of DNA breaks [21]. In brief, stably XRCC3
over-expressing MCF7 cells were seeded in six-well plates at
2610
5 cells/well the day prior to transfection. For each
transfection, the cells were exposed to 250 nM of siRNA in
serum- and antibiotic-free Opti-MEM (Invitrogen) during 4 hours
and then supplemented with 500 ml of RPMI 1640 containing
30% FBS. After 18 hrs, cells (15610
4 cells/0.5 mL) were plated in
the top chamber of a Matrigel-coated invasion plate (BD
Bioscientific) and the invasion capacity of the cells was assessed
as described above.
Zymogram: MMP-9
To assess the presence of pro-MMP-9 and MMP-2 and active
MMP-9 and MMP-2, serum-free, 24 hr-conditioned media was
harvested from sub-confluent cultures of 3610
6 cells. Volumes
representing equivalent cell numbers were concentrated 10 times
by Amicon centrifugation using a 10 kDa cut-off and 30 mlo f
concentrated medium was then separated on 10% SDS-PAGE
containing 0.1% gelatin pre-casted gels (BioRAD). Gels were
incubated in PBS containing 2.5% Triton X-100 at room
temperature for 1 h, followed by further incubation in substrate-
collagenase buffer. Gelatinolytic activity was visualized following
0.5% Coomassie Blue G-250 staining and destaining with 30%
methanol, 10% acetic acid solution. Gels were digitally photo-
graphed and band densitometry performed using Scion image
software (Scion Corporation, Frederick, MA, USA). Equivalent
loading was confirmed by Coomassie staining of a gel run in
parallel and the presence of MMP9 was verified on a parallel gel
treated with 25 mM EDTA as inhibitor of MMP-9 activity.
RNA isolation and RT-PCR (reverse transcription-
polymerase chain reaction)
Total RNA was extracted from MOCK and XRCC3 OE
MCF-7 cells using the RNeasy kit (Qiagen cat#74104). Seven
different cell cultures were used with the number of passages
ranging from 4 to 17. The purity and quantification of all RNA
preparations were monitored using NanoDrop ND-1000 spectro-
photometer.
TFF1 or Sp2. RNA samples were reverse transcribed using
the QuantiTect reverse transcription kit (Qiagen cat#205313) and
expression was analyzed by quantitative real time PCR using
primers as follows: TFF1, forward 59-accatggagacaaggtgat-39 and
reverse 59-aaattcacactcctcttctg-39; and GAPDH as an internal
control, forward 59-tgcaccaccaactgcttagc-39 and reverse 59-
XRCC3 Over-Expression and Cell Invasiveness
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triplicate in a Sybr Green PCR master mix (ABI cat#4309155)
containing 0.25 mM of each primer. Conditions for amplification
were 10 min at 95uC followed by 40 cycles at 95uC, 15 s; and
60uC, 60 s; in a 7500 real time PCR system (ABI). A melting curve
analysis was included to monitor PCR specificity.
CD44. CD44 mRNA expression was analyzed by semi-
quantitative One-Step RT-PCR assay (Qiagen cat# 210210)
using 0.25 mM of forward primer 59gacacatattgcttcaatgcttcagc 39
and a reverse primer 59-gatgccaagatgatcagccattctggaa-39 [30]. The
reactions were performed in triplicate and the conditions for
reverse-transcription and PCR were 1 cycle of 30 minutes at 55uC
followed by a denaturation step of 2 minutes at 94uC, and 35
cycles at 94uC, 15 s; 55uC, 20 s; and 68uC, 30 s. This reaction
results in the amplification of a 482 base-pair fragment that spans
the region between exon 3 and 4 which was visualized by a 2%
agarose gel.
Flow cytometry analysis
A flow cytometric (FCM) analysis was performed to assess
expression of the membrane form of CD44 and membrane and
cellular forms of KU80. We used a FACS-Calibur instrument
(Becton Dickinson) and Cell-Quest software. PE-conjugated
mouse anti-human CD44 (BD-Pharmingen
TM PE 555479)
antibody was used. An isotype-matched antibody (PE-conjugat-
ed rabbit, BD) was used as a control. For KU80, after fixation
with 1% paraformaldehyde at 4uC for 15 minutes, cells were
washed with PBS then, in the case of total KU80 determination
they were permeabilized in 70% cold ethanol for 20 minutes in
ice. After washing in PBS, the cells were incubated 30 minutes at
room temperature in dilution buffer (PBS, 1% BSA, 0.1% triton
X100) and then, incubated overnight at 4uC with a mouse anti-
KU80 antibody (Ab7- MS 332-P0, Neomarkers). The cells were
washed in PBS, and then incubated for 90 minutes with a goat
anti-mouse Alexa Fluor 488 secondary antibody (Molecular
Probe, Eugene, OR, USA) diluted 1:500 in dilution buffer,
washed with PBS, finally analyzed by FCM as previously
described.
Cell fractionation: Nuclear and cytoplasmic extracts
Nuclear and cytoplasmic cell fractionation was performed using
approximately 5610
6 cells homogenized in 200 ml of buffer A
(10 mM HEPES at pH 7.9, 50 mM NaCl, 500 mM sucrose,
0.15 mM spermine, 0.5 mM spermidine, 1.0 mM EDTA, 0.2%
TX-100, mercaptoethanol 7 mM and mini protease inhibitor
cocktail–tablet, Roche). Nuclei were spun out in a refrigerated
microfuge. The supernatant (cytoplasmic extract) was kept for
further use and the pellet was washed in 500 ml of buffer B (as A
with 25% glycerol and without sucrose and TX-100) and then
suspended in 50 ml of buffer C (350 mM NaCl, 10 mM HEPES
pH 7.9, 25% glycerol, 0.15 mM spermine, 0.5 mM spermidine,
1.0 mM EDTA), then centrifuged at 4uC and the supernatant was
stored as nuclear extract.
We assessed expression of XRCC3 and KU80 proteins on 60%
confluent cultures by Western blot of nuclear and cytoplasmic
fractions. Rabbit anti-XRCC3 (Oncogen, San Diego, CA. Ab-1)
was used and mouse anti-p53 (Neomarkers, Ab8) and Rho A
(Santa Cruz Biotechnology, Inc) were used to confirm nuclear and
cytoplasmic fractions.
In vivo studies, mouse xenograft model
Stably transfected MOCK and XRCC3 OE MCF-7 cells were
grown to 70% confluence, and were harvested from the
subconfluent cultures by exposure to 0.25% trypsin and 0.02%
EDTA. Trypsinization was stopped by the addition of medium
containing 10% FBS. Cells were kept at 4uC until use (0–1 hour).
Cell concentration and viability (Trypan blue exclusion, 90%
viability) were determined using a hemocytometer. Seven and
eight C.B17 SCID female mice (Fox Chase Scid-Charles River)
were injected subcutaneously into the flanks with 1.5610
6
exponentially growing MOCK and XRCC3 OE MCF-7 cells,
respectively, in 100 ml of sterile PBS, pH 7.4. The female mice of
10 weeks old were used for xenograft studies in accordance with
the guidelines of the Canadian Council on Animal Care and with
appropriate institutional certification (Animal Welfare Assurance
No.A5006-01, IACUC status approved -11/01/2009- McGill
University Animal Care Committee and Jewish General Hospital,
Montreal, Canada).
Tumour growth was confined to local masses and did not affect
animal survival over a 6-month observation period. Tumour
volumes were monitored weekly by caliper measurement of the
length and width, and their volumes calculated according to the
modified ellipsoidal formula (V= (l x w
2)/2) [31]. The mice were
sacrificed and tumours were collected and fixed in paraffin when
the tumours reached more than 100 mm
3.
Immunohistochemistry
Immunoperoxidase staining for PCNA and XRCC3 was
performed by the avidin-biotin complex method (Vector
Laboratories, Burlingame, CA). 4-mmf o r m a l i nf i x e dp a r a f f i n
embedded sections were cut, placed on SuperFrost/Plus slides
(Fisher), and dried overnight at 37uC. Sections were deparaffi-
nised in xylene and rehydrated through graded alcohols to water;
then they were immersed in 10 mM sodium citrate buffer,
pH 6.0, and subjected to heat-induced antigen retrieval.
Endogenous peroxidase activity was quenched by incubation in
3% hydrogen peroxide for 15 min. Endogenous biotin was
blocked by incubation for 10 min with the Avidin/Biotin
blocking kit (Zymed Laboratories Inc., San Francisco, CA). To
block non specific protein binding, sections were then treated
with 5% normal goat serum in PBS-Tween 0.1% (PBS-T) for
60 min at room temperature. Sections were incubated overnight
at 4uC with primary antibodies at appropriate dilutions made in
blocking solution: mouse anti-PCNA (Novocastra) at 1:100 and
rabbit anti-XRCC3 1:25 (Abcam, Inc.). After rinsing with PBS-
T, sections were incubated with biotinylated antibodies (goat
anti- mouse or goat anti-rabbit, Vector Laboratories) for 60 min
at room temperature. The sections were then incubated for
30 min with avidin-biotin-horseradish peroxidase complex
(Vector Laboratories), followed by final color development with
peroxidase substrate kit DAB (Vector Laboratories) for 3–5 min.
A negative control was performed by the omission of the primary
antibody. Sections were then lightly counterstained with
hematoxylin, dehydrated in graded alcohols, cleared in xylene
and coverslipped. Sections were analyzed by conventional light
microscopy.
Statistical and image analysis
Statistical analyses were performed using Sigma Stat and
PlotStat packages. The analysis included the Mann-Whitney U
test and Student’s unpaired and paired t test (for two groups).
Comparison among group tumour incidence was performed by a
Kaplan Meier analysis and plot and the probability of a trend in
the incidence score through a logrank test. Data are expressed as
fold differences between means and were considered significant at
P,0.05. For image analysis ImageJ 1.41o or Scion Corporation
software was used.
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16394Figure 1. Assessing the invasion phenotype of XRCC3 over-expressing cells. (A) Independent XRCC3 and RAD51 transient transfections
were assayed and their protein expression was assessed through Western Blot. (B) MOCK and RAD51 or XRCC3 OE BT20 and MCF-7 cells were seeded
onto Matrigel covering the surface of a porous membrane. Cells were incubated for 48 hrs to allow penetration of the matrix. Invading cells were
subsequently fixed using 3.7% formaldehyde solution and stained using Hematoxylin-EosinY (Thermo Scientific). Migrating/invading cells were
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Changes in the expression of XRCC3 but not RAD51
modulate the invasiveness of human breast cancer cells
in vitro
XRCC3 and RAD51 over-expression was assessed by Western
blot. RAD51 and XRCC3 transient transfected MCF-7 and BT20
cells over-expressed RAD51 or XRCC3 by 2- to more than 10-fold,
when compared with MOCK-transfected cells (Fig. 1A). MCF-7
stably transfected with XRCC3 overexpress XRCC3 by more than
3-fold, when compared with the stably transfected MOCK cells
(Table 1). Using a Boyden chamber assay, a classical method to
assess invasiveness also named trans-well migration assay
[17,32,33,34], we found that XRCC3 over-expressing MCF-7 and
BT20 cells (XRCC3 OE hereafter)weretwo-fold moreinvasivethan
their mock transfected counterparts (MOCK hereafter) (Fig. 1B–C).
These increases in invasiveness were statistically significant with p
values of ,0.01 and 0.002 for MCF-7 cells and BT20 cells
respectively. The higher invasive phenotype was exclusively
observed on XRCC3 OE cells and not on cells over-expressing
RAD51 (RAD51 OE hereafter) and the increase in invasiveness was
dependent on the level of expression of XRCC3 (Figure S1). The
increase in XRCC3 OE cells invasiveness and its dependency on
XRCC3 protein expression levels was also confirmed through gene
silencing of the Xrcc3 gene by small interfering RNA in MCF-7 cells
stably over-expressing XRCC3 (Figure S2).
XRCC3 over-expression affects the expression of
biomarkers associated with metastasis in human breast
cancer cells
We analyzed MMP-2 and MMP-9 enzymatic activity in MCF-7
conditioned media by gelatin zymography. As shown in Fig. 2A,
the gelatinolytic bands of 84 and 92 kDa of MMP-9 were
increased more than two- and four-fold, respectively, in the culture
supernatant of XRCC3 OE cells with respect to MOCK cells
(P,0.01). In contrast, the 72-kDa gelatinolytic band, representing
the product of the MMP-2 gene was unchanged by XRCC3
expression level (Fig. 2A). We also confirmed a significantly
increased level of MMP-9 protein in XRCC3 OE MCF-7 cells
lysates by Western blot analysis (Table 1). MMP-9 protein levels
were up four-fold in XRCC3 OE cells with respect to MOCK cells
(P=0.03) (Fig. 2B, Table 1).
In contrast, to the proteins mentioned above, two other
proteins KU80 (XRCC5) and KU70 (XRCC6) showed no
significant differences between MOCK and XRCC3 OE MCF-7
cells with respect to the expression or cellular localization when
analyzed by flow cytometry and Western blot analysis of cell
fractions (Table 1).
In addition, using flow cytometry we found that XRCC3 OE
MCF-7 cells expressed significantly higher levels of CD44 protein
than MOCK cells as represented by the number of CD44
positive cells in the flow cytometric analysis (2-fold, P=0.041)
( F i g .2 C ) .As i m i l a rr e s u l tw a so b tained using semi-quantitative
reverse transcription PCR were a 2-fold increase in CD44
mRNA expression was observed in XRCC3 OE cells (Fig. 2D,
Table 1).
Using the QuantiTect reverse transcription kit (Qiagen
cat#205313) and quantitative real time PCR we also found that in
XRCC3 OE cells, TFF1 mRNA level was two-fold higher in XRCC3
OE MCF-7 cells compared to MOCK cells (P,0.001) (Table 1).
We found by Western blot that ID-1 and DDR1 protein levels
were also significantly increased in cell lysates, more than 3-fold
(P=0.043 and P=0.029, respectively) in XRCC3 OE cells with
respect to MOCK cells (Fig. 2E, Table 1).
Table 1. Expression of biomarkers associated with metastasis or invasion analyzed by different methods in MCF-7 cells.
MARKER Fold differences MOCK XRCC3 OE P value METHOD
CD44 protein 2.6 22%675 7 % 612 0.041 FCM*
CD44 mRNA 2.5 0.460.05 1.060.03 ,0.001 RT-PCR, Semi-
quantitative
p
DDR1 protein 3.8 0.460.16 1.660.43 0.029 Western blot
¥
ID-1 protein 9.0 0.160.06 1.260.48 0.043 Western blot
KU70 total protein 1.0 1.160.25 1.160.26 0.979 Western blot
KU80 total protein 1.0 0.860.21 0.960.01 1.000 Western blot
KU80, membrane associated form 1.3 34%674 1 % 64 0.333 FCM
MMP-9 protein 4.5 0.460.18 1.860.48 0.033 Western blot
Pro-MMP-9 protein 3.4 2863.96 9663.62 ,0.001 Zymogram
Active-MMP-9 protein 2.0 4267.77 87613.8 0.045 Zymogram
XRCC3 protein 3.0 0.460.15 1.360.25 0.024 Western blot
XRCC3 -OE 1 protein 10.0 0.1 1.0 N.A. Western blot
XRCC3 -OE 2 protein 20.0 0.1 2.0 N.A. Western blot
TFF1/pS2 mRNA 2.4 Relative expression to MOCK 0.001 RT-PCR Quantitative
*% of cells expressing CD44 or KU80 on the outer membrane by flow cytometry analysis;
p values are relative to GAPDH mRNA expression;
¥ values are relative to Actin expression.
doi:10.1371/journal.pone.0016394.t001
counted. (C) Data was then plotted as mean cells per field 6SD for a minimum of three separate experiments, each in duplicate. XRCC3 OE cells had a
much higher degree of basal motility and invasion than did their MOCK BT20 and MCF-7 counterparts (2 fold higher, P,0.01) while RAD51 OE cells
were not significantly different from MOCK cells.
doi:10.1371/journal.pone.0016394.g001
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capacity of MCF-7 cells in vivo
We subcutaneously injected SCID mice with equal numbers of
MOCK or XRCC3 over-expressing MCF-7 cells (1.5610
6 cells) in
the absence of oestradiol treatment. The tumour incidence was
highly increased (P=0.028) in mice injected with XRCC3 OE
cells. After 12 weeks, 4/7 mice injected with XRCC3 OE showed
tumours compared to 1/8 mice injected with MOCK cells
(Fig. 3B). In addition, the xenograft analysis showed rapid tumour
formation on those mice injected with XRCC3 OE cells. Mice
injected with XRCC3 over-expressing cells developed tumours
with volumes ranging from 1 to 8 mm
3 at 4 weeks post injection.
In contrast, at week ten post-injection we detected a 0.5 mm
3
tumour in a mouse injected with MOCK cells (data not shown).
The mice were sacrificed when tumours exceeded 100 mm
3 and
tumours were collected and fixed in paraffin. The analysis of
immunohistochemistry stainings for PCNA and XRCC3 showed
no significant differences for PCNA expression; in contrast the
expression of XRCC3 was shown in the cytoplasm and nucleus
and was four-fold higher in the periphery of the XRCC3 OE cell
tumours where 61% of the cells showed high nuclear staining. In
contrast only 14% of MOCK tumour cells showed high levels of
nuclear XRCC3 (P=0.029) (Fig. 3A).
Discussion
Our results demonstrate that 2-3 fold increase in the expression
of XRCC3 protein levels is sufficient to significantly increase the
invasive behaviour of two human breast cancer cell lines (MCF-7
and BT20) in vitro. These findings suggest that the proposed role of
XRCC3 in the modulation of invasiveness might not be exclusive
of a breast cancer subtype since MCF-7 is a luminal epithelial-like
cell while BT20 is a triple negative basal-like cell line. Importantly,
the increased invasiveness associated with XRCC3 over-expres-
sion was observed in both, stable and transient XRCC3 over-
expressing cells suggesting that the effect is not likely due to
secondary phenotypic alterations associated with clonal selection.
The specificity of the effect of XRCC3 expression in invasion is
further supported by the following two observations reported in
this manuscript: 1) the dose effect, higher XRCC3 over-expression
displayed higher invasive capacity and 2) decreasing levels of
XRCC3 from treatment with a specific Xrcc3 siRNA led to
decreasing invasive capacity.
Consistently with the changes in the invasive behaviour of the
cells, we found that increased expression of XRCC3 resulted in
increased activity of MMP-9, a gelatinase involved in the
extracellular matrix (ECM) degradation that is thought to play
an important role in cancer metastasis [16,18,19,20]. Moreover,
we found that the XRCC3 over-expression resulted in increased
expression of CD44, the Discoidin Domain Receptor 1 (DDR1)
and ID-1. These three biomarkers have been associated with
increased invasiveness of cancer cells and/or localization and
modulation of MMP-9 function [16,32,35,36,37,38,39]. CD44 has
been shown to anchor the proteolytically-active form of MMP-9 to
the cell surface [19] while the constitutive expression of either the
transcription factor ID-1 or the receptor DDR1 has been reported
to increase the activity of MMP-9 and the invasiveness of human
cancer cells (35–39). These results demonstrate that XRCC3
expression can alter the expression/activity of a network of
proteins associated with ECM metabolism, one of the key steps
involved in cell invasion. Furthermore, XRCC3 over-expression
resulted in a significant increase in the expression of the human
trefoil protein TFF1 a modulator of cell motility, another key step
required for cell invasion and metastasis. It has been shown that
TFF1 (also known as pS2) stimulates the movement of MCF-7 and
other breast cancer cells and promotes their dissemination by
preventing anoikis [40,41,42,43]. MCF-7 breast cancer cells
expressing a higher level of TFF1 have an increased capacity to
spread by invading surrounding tissues thus conferring them with
a more invasive/metastatic phenotype [40,41,42,43].
Taken together with our in vitro results, we demonstrated that
XRCC3 expression levels affect the invasiveness of breast cancer
cells, the expression/activity of targets associated with the
regulation of invasiveness (i.e. TFF1), the interaction of cancer
cells with the extracellular matrix (i.e. ID-1, DDR-1 and CD44)
and the extracellular matrix turnover (i.e. MMP-9).
In an attempt to support the in vitro results we assessed the effect
of XRCC3 over-expression on the growth of MCF-7 tumour
xenografts in SCID mice under suboptimal conditions (i.e. in the
absence of oestradiol treatment). MCF-7 has been reported to
grow tumours poorly without oestradiol treatment in SCID mice
[44,45]. Our results show that XRCC3 favours the growth of
MCF-7 xenografts since the growth rate of tumours was roughly
five times higher for XRCC3 over-expressing cells when
compared to the control type (i.e. 57% vs. 12% respectively).
Importantly, immnocytochemical analysis using a specific XRCC3
antibody confirmed the over-expression of the protein in the
xenograft tumour tissues. XRCC3 expression was four-fold higher
in the XRCC3 OE cell tumours. Furthermore, 61% of XRCC3
OE tumour cells showed high nucleus staining compared with
14% of MOCK tumour cells. Interestingly, similar to previous
reports [46], the tumours showed not only nuclear but also
cytoplasmic XRCC3 staining in both kinds of xenograft derived
tissues.
Even though it has been shown that XRCC3 over-expression
does not affect the doubling time of MCF-7 cells in vitro [7], the
effect in vivo has not been tested. To discard a possible effect of
XRCC3 over-expression on the doubling time of MCF-7 cells in
vivo, we investigated the expression of the Proliferating Cell
Nuclear Antigen, PCNA. PCNA is an auxiliary protein of DNA
polymerase whose level of synthesis correlates directly with rates of
cellular proliferation and DNA synthesis; and it has been widely
used as a marker to assess the mitotic index of tumour cells
[47,48]. In agreement with previous in vitro reports, XRCC3 over-
expression did not affect the proliferative capability of MCF-7
cells, since there was no significant difference in PCNA expression
between the MOCK and XRCC3 OE tumours.
Our results demonstrate that stable or transient over-expression
of XRCC3 increases in vitro invasiveness in two breast cancer cell
lines from different lineage (luminal and triple negative). Though
we still lack a clear mechanism of how XRCC3, a protein
associated with HRR, could affect the invasive phenotype of the
Figure 2. Characterization of the expression of proteins associated with ECM metabolism and invasion. (A) Zymography shows MMP-2
and MMP-9 activity in serum free MCF-7 conditioned medium. The gelanolytic bands of 84 (active) and 92 kDa (pro-active) MMP-9 were increased
two- and more than three-fold, respectively (P=0.045 and P,0.001), in XRCC3 OE cells with respect to MOCK cells (P,0.01); while there were no
differences for MMP-2 bands. (B) MMP-9 protein levels were increased 4-fold in XRCC3 OE cells compared to MOCK cells (P=0.033). (C) Using flow
cytometry, we found that XRCC3 OE cells expressed significantly higher levels of CD44 protein than MOCK cells (two-fold, P=0.041). (D) Using semi-
quantitative reverse transcription PCR a two-fold increase in CD44 mRNA expression was observed in XRCC3 OE cells (P,0.001). (E) ID-1 and DDR1
protein levels were significantly increased (P=0.043 and P=0.029, respectively) in XRCC3 OE cells with respect to MOCK cells.
doi:10.1371/journal.pone.0016394.g002
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were associated with increased activity of the metalloproteinase
MMP-9 and the expression of known modulators of cell-cell
adhesion and metastasis such as CD44, ID-1, DDR1 and TFF1.
Moreover, XRCC3 over-expressing cells showed a higher
tumorigenesis and higher XRCC3 expression in vivo.
XRCC3 plays an important role in both DNA repair and
resistance to anticancer agents that induce DNA damage (6, 20–
25). Our results indicate that over-expression of the XRCC3 gene
is also associated with an invasive behaviour in vitro and the
promotion of tumour formation in vivo, these features were
independent of RAD51 and the proliferation rate of the cells. In
addition, XRCC3 did not alter the expression levels of the
membrane form of KU80, another DNA repair-related gene
(designated XRCC5) that functions as a docking protein for
MMP-9 at the cell surface [16,17,33]. These results taken together
suggest that XRCC3 can affect MMP-9 activity independently of
KU80 or KU70 (XRCC6).
In summary, the recently established XRCC3 over-expressing
MCF-7 cell line [7] is a promising model for the study of drug
resistance and malignant progression associated with DNA-repair
pathways. This is the first report that provides experimental results
showing that a DNA repair protein is involved in the regulation of
invasiveness and tumour growth in human breast cancer cells and
suggests that XRCC3 expression could be used as a biomarker for
breast tumour growth and development.
Supporting Information
Figure S1 Invasiveness is dependent of XRCC3 expres-
sion level. Two independent XRCC3 transient transfections
were assayed on MCF-7 cells. XRCC3 OE cells showed a higher
level of basal invasion than MOCK cells and the rate of invasion
(A) corresponds to the level of XRCC3 protein over-expression
detected by Western blot analysis (B) where XRCC3-OE 1 and
XRCC3-OE 2 showed an increased expression of more than ten-
and twenty-fold.
(TIF)
Figure S2 XRCC3 siRNA of MCF-7 stably over-express-
ing XRCC3 reverts the phenotype to a lesser invasive
one. (A) Western blotting analysis of XRCC3 protein after
transfection by XRCC3 siRNA of MCF-7 cells stably over-
expressing XRCC3, XRCC3 protein was recognized by anti-
XRCC3 antibody (Oncogen). GAPDH (Research Diagnostics) was
used as a loading control. XRCC3 protein expression of XRCC3
OE cells was reduced in a 23 to a 47%; (B) Invasion data for two
separate experiments, each in triplicate. The siXRCC3 XRCC3
OE cells invasion relative to siControl showed less basal invasion
than did their siControl-XRCC3 OE cells when the XRCC3
protein expression was reduced in 38 to 47% from the expression
of their siControl-XRCC3 OE counterpart though to obtain a
statistically significant effect on invasion XRCC3 has to be
reduced more than the 40% of its protein expression.
(TIF)
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